Receptor binding cancer antigen expressed on SiSo cells, a novel regulator of apoptosis of erythroid progenitor cells.
To better understand the control of apoptosis during erythropoiesis, this study investigated the role of a novel tumor-associated antigen, RCAS1 (receptor binding cancer antigen expressed on SiSo cells), with regard to the regulation of apoptosis of erythroid progenitor cells. Erythroid colony-forming cells (ECFCs) purified from human peripheral blood were used. Binding experiments of RCAS1 showed that ECFCs abundantly expressed receptors (RCAS1R) for RCAS1 and that the degree of binding of RCAS1 to the receptors diminished rapidly during erythroid maturation in vitro. When the soluble form of RCAS1 was added to the cultures, ECFCs underwent apoptosis, including collapse of the mitochondrial transmembrane potential, and activation of caspases 8 and 3. The addition of an anti-Fas blocking antibody or Fas-Fc failed to reduce the apoptosis induced by RCAS1, thereby indicating that effects of RCAS1 are independent of Fas activation. When binding of RCAS1 to normal bone marrow cells was analyzed, RCAS1R was evident on cells with an immature erythroid phenotype (transferrin receptor(+)/glycophorin A(-)) but not with a mature phenotype (transferrin receptor(-)/glycophorin A(+)). Histochemical staining revealed the expression of RCAS1 in the cytoplasm of bone marrow macrophages. These findings indicate that RCAS1, which is mainly produced by macrophages in hematopoietic tissue, may have a crucial role in controlling erythropoiesis by modulating apoptosis of erythroid progenitor cells via a Fas-independent mechanism.
Matsushima
T
T
Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
Nakashima
M
M
Oshima
K
K
Abe
Y
Y
Nishimura
J
J
Nawata
H
H
Watanabe
T
T
Muta
K
K
D000230:Adenocarcinoma; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000378:metabolism; D000954:Antigens, Surface / Q000032:analysis* / Q000378:metabolism / Q000494:pharmacology; D017209:Apoptosis / Q000502:physiology*; D001854:Bone Marrow Cells / Q000737:chemistry / Q000166:cytology / Q000378:metabolism; D053148:Caspase 3; D053181:Caspase 8; D053453:Caspase 9; D020169:Caspases / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D003114:Colony-Forming Units Assay; D003593:Cytoplasm / Q000737:chemistry; D004789:Enzyme Activation; D015672:Erythroid Precursor Cells / Q000737:chemistry / Q000502:physiology*; D004921:Erythropoietin / Q000494:pharmacology; D005260:Female; D006021:Glycophorins / Q000032:analysis; D006098:Granulocytes; D006651:Histocytochemistry; D006801:Humans; D008264:Macrophages; D008564:Membrane Potentials / Q000187:drug effects; D011956:Receptors, Cell Surface / Q000032:analysis / Q000378:metabolism; D011990:Receptors, Transferrin / Q000032:analysis; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured; D014594:Uterine Neoplasms; D019014:fas Receptor / Q000502:physiology
D000951:Antigens, Neoplasm; D000954:Antigens, Surface; C120762:EBAG9 protein, human; D006021:Glycophorins; D011956:Receptors, Cell Surface; D011990:Receptors, Transferrin; D011994:Recombinant Proteins; D019014:fas Receptor; D004921:Erythropoietin; C505407:CASP3 protein, human; C505530:CASP8 protein, human; C506433:CASP9 protein, human; D053148:Caspase 3; D053181:Caspase 8; D053453:Caspase 9; D020169:Caspases